Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

dustin1101 Feb. 3 at 4:04 PM

$AXGN Breakout watch again..

0 · Reply

dustin1101 Feb. 3 at 2:44 PM

$AXGN Looks to me like we have some weak hands from an alert yesterday afternoon.. didn’t quite realize how thin this one can be.

0 · Reply

dustin1101 Feb. 2 at 2:45 PM

$AXGN Cannacord from $37 -> $40 PT this morning.

0 · Reply

StockConsultant Feb. 2 at 2:26 PM

$AXGN Axogen stock, watch for a top of range breakout at https://stockconsultant.com/?AXGN

0 · Reply

dustin1101 Jan. 30 at 8:53 PM

$AXGN Beautiful

1 · Reply

dustin1101 Jan. 29 at 6:38 PM

$AXGN Still flagging out from the push Monday. Considering the mkt its doing quite nicely. HODL.

0 · Reply

dustin1101 Jan. 27 at 3:40 PM

$AXGN starting the day with a shakeout. Not too surprised tbh.

0 · Reply

LuckEtradER Jan. 27 at 6:19 AM

$AXGN

0 · Reply

JesusIsKing1 Jan. 26 at 9:26 PM

$ABAT lowered my average here today. Down 62 bloody %. Bought this at 10 like a fomo idiot and also bought a big chunk of $AXGN

2 · Reply

JesusIsKing1 Jan. 26 at 8:05 PM

$AXGN added. The chart is so freaking great. Looks like there is plenty more upside and I don't want to miss this ride.

1 · Reply

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

Jan 21, 2026, 4:09 PM EST - 13 days ago

Axogen Announces Proposed Public Offering of Common Stock

Jan 15, 2026, 5:25 PM EST - 19 days ago

Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 22 days ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 2 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 2 months ago

FDA approves Axogen's nerve repair graft

Dec 1, 2025, 12:33 PM EST - 2 months ago

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Nov 5, 2025, 2:19 PM EST - 3 months ago

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Oct 29, 2025, 2:26 PM EDT - 3 months ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:00 AM EDT - 3 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 4 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 10:50 AM EDT - 4 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 6:40 AM EDT - 5 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 12, 2025, 5:17 AM EDT - 6 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 5, 2025, 1:15 PM EDT - 6 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:10 PM EDT - 6 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 7 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

May 28, 2025, 8:00 AM EDT - 8 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 9, 2025, 3:21 PM EDT - 9 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:05 AM EDT - 9 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 10 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Feb 25, 2025, 1:58 PM EST - 1 year ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:01 PM EST - 1 year ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 11:03 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

dustin1101 Feb. 3 at 4:04 PM

$AXGN Breakout watch again..

0 · Reply

dustin1101 Feb. 3 at 2:44 PM

$AXGN Looks to me like we have some weak hands from an alert yesterday afternoon.. didn’t quite realize how thin this one can be.

0 · Reply

dustin1101 Feb. 2 at 2:45 PM

$AXGN Cannacord from $37 -> $40 PT this morning.

0 · Reply

StockConsultant Feb. 2 at 2:26 PM

$AXGN Axogen stock, watch for a top of range breakout at https://stockconsultant.com/?AXGN

0 · Reply

dustin1101 Jan. 30 at 8:53 PM

$AXGN Beautiful

1 · Reply

dustin1101 Jan. 29 at 6:38 PM

$AXGN Still flagging out from the push Monday. Considering the mkt its doing quite nicely. HODL.

0 · Reply

dustin1101 Jan. 27 at 3:40 PM

$AXGN starting the day with a shakeout. Not too surprised tbh.

0 · Reply

LuckEtradER Jan. 27 at 6:19 AM

$AXGN

0 · Reply

JesusIsKing1 Jan. 26 at 9:26 PM

$ABAT lowered my average here today. Down 62 bloody %. Bought this at 10 like a fomo idiot and also bought a big chunk of $AXGN

2 · Reply

JesusIsKing1 Jan. 26 at 8:05 PM

$AXGN added. The chart is so freaking great. Looks like there is plenty more upside and I don't want to miss this ride.

1 · Reply

PlungeherRawan Jan. 26 at 6:36 PM

$AXGN a 5 yr cup and handle. This is only the first leg up.

0 · Reply

JFDI Jan. 26 at 6:17 PM

$AXGN gorgeous

0 · Reply

dustin1101 Jan. 26 at 6:16 PM

$AXGN From the last health care conference transcript.

0 · Reply

topstockalerts Jan. 26 at 5:19 PM

$AXGN This setup keeps producing tradable moves. Buyers are consistently supporting price. Momentum remains favorable.

0 · Reply

Albino_Trader123 Jan. 26 at 5:13 PM

$AXGN Interesting looking High Tight Flag here. Trading above upsized offering. Breaking out of Hight Tight Flag. Bullish

0 · Reply

dustin1101 Jan. 26 at 4:16 PM

$AXGN Breakout watch here..

0 · Reply

dustin1101 Jan. 26 at 3:05 PM

$AXGN

0 · Reply

dustin1101 Jan. 23 at 8:31 PM

$AXGN Not sure what else one needs to confirm that this chart is bullish AF. Took a 4M share offering in stride, literally an inside bar on the weekly and never traded below secondary price in regular hours. Wild

1 · Reply

dustin1101 Jan. 23 at 8:08 PM

$AXGN I’d say offering is closed. PR after close probably.

0 · Reply

jlsnet22 Jan. 22 at 8:57 PM

$AXGN Is anyone else surprised this company did an equity raise today when it’s supposed to be cash flow positive this year?

1 · Reply

dustin1101 Jan. 22 at 4:06 PM

$AXGN Holding well above offering price. Super strong. Balance sheet getting simplified and 💪🏻.. Still think a buyout is likely here.

0 · Reply

dustin1101 Jan. 22 at 2:53 PM

$AXGN Jefferies now at a $40 target today.

0 · Reply

Market Cap	1.61B
Revenue (ttm)	187.34M
Net Income (ttm)	-9.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	200.00
Profit Margin	-5.32%
Debt to Equity Ratio	0.40

Volume	1,087,124
Avg Vol	991,838
Day's Range	N/A - N/A
Shares Out	46.12M
Stochastic %K	78%
Beta	1.00
Analysts	Strong Sell
Price Target	$37.00